Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

Summary Background Most patients who have active Crohn's disease are treated initially with corticosteroids. Although this approach usually controls symptoms, many patients become resistant to or dependent on corticosteroids, and long exposure is associated with an increased risk of mortality....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2008-02, Vol.371 (9613), p.660-667
Hauptverfasser:	D'Haens, Geert, MD, Baert, Filip, MD, van Assche, Gert, MD, Caenepeel, Philip, MD, Vergauwe, Philippe, MD, Tuynman, Hans, MD, De Vos, Martine, MD, van Deventer, Sander, MD, Stitt, Larry, MSc, Donner, Allan, Prof, Vermeire, Severine, MD, Van De Mierop, Frank J, MD, Coche, Jean-Charles R, MD, van der Woude, Janneke, MD, Ochsenkühn, Thomas, MD, van Bodegraven, Ad A, MD, Van Hootegem, Philippe P, MD, Lambrecht, Guy L, MD, Mana, Fazia, MD, Rutgeerts, Paul, Prof, Feagan, Brian G, Prof, Hommes, Daniel, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenal Cortex Hormones - therapeutic use Antibodies, Monoclonal - therapeutic use Azathioprine - therapeutic use Belgium Chi-Square Distribution Clinical medicine Corticoids Crohn Disease - drug therapy Crohn's disease Disease management Drug therapy Female Germany Humans Immunosuppressive Agents - therapeutic use Infliximab Internal Medicine Male Methotrexate - therapeutic use Mortality Mortality risk Netherlands Patients Pharmaceuticals Physical examinations Quality of life Statistics, Nonparametric Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!